Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Protein phosphatase 2A (PP2A) is crucial for regulating apoptosis, proliferation, and DNA-damage response.
• PP2A is frequently overexpressed in cancers, including small cell lung cancer (SCLC).

Purpose of the Study:

• To investigate the efficacy of LB100, a PP2A inhibitor, in combination with platinum-based chemotherapy and immunotherapy for SCLC treatment.
• To elucidate the mechanisms underlying LB100's synergistic effects in SCLC.

Main Methods:

• In vitro and in vivo studies using SCLC cell lines and spheroid models.
• Inductively coupled plasma mass spectrometry (ICP-MS) to quantify drug uptake.
• Assessment of cell viability, glucose uptake, ATP production, T cell infiltration, DNA damage marker (γH2AX) phosphorylation, apoptosis, MET signaling, and invasion.

Main Results:

• LB100 synergistically enhanced the antitumor response of platinum-based chemotherapy in SCLC with no apparent toxicity.
• LB100 increased carboplatin uptake in SCLC cells, inhibited cell viability, reduced glucose uptake, and attenuated ATP production.
• Combination therapy with LB100 and atezolizumab improved T cell infiltration and tumor cell killing; combination with carboplatin enhanced apoptosis and DNA damage while reducing MET signaling and invasion.

Conclusions:

• LB100 demonstrates significant translational potential as a combination therapy for SCLC.
• Inhibiting PP2A with LB100 offers a promising strategy when combined with chemotherapy and immunotherapy for SCLC treatment.